ENTA

In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report), with a price target of $103.00. The company's shares closed last Wednesday at $45.97, close to its 52-week low of $40.37. According to TipRanks.com, Buchanan has 0 stars on 0-5 stars ranking scale with an average return of -17.3% and a 27.5% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma, Hookipa Pharma, and CureVac. Enanta Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $78.78, implying a 65.1% upside from current levels.
https://www.tipranks.com/news/blurbs/jmp-securities-reaffirms-their-buy-rating-on-enanta-pharmaceuticals-enta?utm_source=advfn.com&utm_medium=referral